The key question here is whether sarcomatoid carcinomas of the lung with high PD-L1 expression and treatable oncogenic driver mutations should receive immunotherapy or, according to current guidelines, targeted therapy first. The gene discussed is CD274; the disease is lung sarcomatoid carcinoma.